Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in BIOCORP
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
Advertisement
NLS News
More than 18,000 delegates from 85 countries are attending the event in Boston, USA. The BIO International Convention offers intensive networking to discover new opportunities and promising partnerships. The program
Corporate social responsibility (CSR) has become an integral part of business operations in the Nordic region, with companies prioritizing sustainable practices and demonstrating a commitment to social and environmental responsibility.
Qlucore has presented the first results from an EU-funded project for improved diagnosis of lung cancer. The presented results, a new classification model, not only separates different subgroups of primary
InDex Pharmaceuticals has announced that a license agreement has been signed with Viatris Pharmaceutical Japan to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis. “We are
A national COVID-19 biobank sample collection has been added to the COVID-19 Sample Collection Database, which is available through the Swedish Pandemic Preparedness Portal. This collection includes over 1.5 million
Oncopeptides has been informed that the preliminary investigation by the Swedish Economic Crime Authority of the company’s Chief Scientific Officer and former CEO, Jakob Lindberg, has been terminated. In their
ProPharma announces new office located in Ideon Science Park, effective on June 1, 2023. Ideon Science Park provides abundant opportunities and accessibility for individuals in the Öresund region, encompassing Lund,
Getinge has announced an agreement to acquire 100% of the shares in High Purity New England, a US-based company in the areas of custom single-use solutions for bioprocessing applications. “This
The capital injection will be used to further develop the company’s unique process that enables discovery and manufacture of next generation cell therapies for cancer on an industrial scale. The
The Iceland-founded biopharmaceutical company was officially listed on the Nasdaq stock exchange in New York, making it the first Icelandic VC portfolio company to go public. Both Klappir and Solid
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending once-weekly Sogroya (somapacitan) for replacement of
The focus on real world evidence (RWE) and its potential to support regulatory decision-making has gained global traction. Regulatory bodies, such as the European Medicines Agency (EMA) and the US
The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to the company’s lead asset mitazalimab for the treatment of pancreatic cancer. “This designation is a key milestone
Sponsored content
Multi-pass Transmembrane Protein Development Platforms
Membrane proteins comprise approximately 60% of current drug targets and are a constant focus in pharmaceutical and biological research. Sino Biological is a leader in manufacturing high-quality multi-pass transmembrane protein products, such as Claudins, GPRC5D, SSTR2, and CXCR4. The company’s VLP, detergent micelle, and SMA-nanodisc platforms based on the HEK293 expression system generate premium raw materials for early-stage drug development. Additionally, Sino Biological offers custom multi-pass transmembrane protein services based on the three platforms.
Drug and Device Development
Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee
Evaxion Biotech to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma at the 2023 ASCO annual meeting. “We are excited to report that the
A vaccine against Lyme disease is now being tested in Sweden. “A new vaccine will probably be on the market within a couple of years,” says Johan Sanmartin Berglund, Professor
AnaMar has announced results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis (SSc) characterized by lung
AlzeCure Pharma has received positive data from the clinical study with the non-opioid drug candidate ACD440, which is developed against peripheral neuropathic pain. The phase II data show that ACD440
Profile
The philosophical aspect of chemistry led Morten Meldal to the field and he loves, and cannot help thinking about, the next solution and the intriguing questions about our being and
Iris Öhrn considers herself a cosmopolitan person, and with good reason. The investment advisor for life science at Business Region Göteborg left her native Cuba to study and work abroad
Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD,
Careers
Isa Lindgren has been intrigued by all things science since she was a child. As Manager of Analytical Development at NorthX Biologics she gets to integrate her fascination with a
SwedenBIO has appointed the co-founder and operational manager of Sprint Bioscience, Jessica Martinsson, as its new Director General. “With her entrepreneurial experience and co-founder of a life science company, SwedenBIO
Evaxion Biotech has announced that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 3rd. “With Per at the steering wheel, we expect to bring
Careers
Tanja Dowe, Head of Debiopharm Innovation Fund, gives us her insights from the hard but exciting work of building a life science business and what it takes to make it
JOB ALERTS
Read the latest issue of our magazine!
No 02 2023 // This issue includes an exclusive profile interview with Deborah Dunsire, President and CEO of Lundbeck, a careers interview with the new chairman of Medicon Valley Alliance, Niels Abel Bonde, and an investor interview with Pekka Simula, Partner at the Finnish VC firm Innovestor.
We also take a closer look at post-pandemic lessons in the USA, life sciences in the UK after Brexit and the journey to market for micro-sized and small companies. Helena Strigård, NorthX Biologics, writes about the importance of aiming high in times of economic turmoil, and Hanne Mette Dyrlie Kristensen, The Life Science Cluster, describes the awakening of Norwegian life science.
We have also sniffed out a few Nordic companies involved in some of the great medical breakthroughs that have been made in recent years; the development of cancer vaccines, transplantation of gene-modified organs, early detection of cancer, groundbreaking discoveries using unique health data, a revolutionary anti-obesity drug and great progress made within gene therapy.
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
The BIO International Convention attracts 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. Innovative programming around the current and future
Focusing on core pharmaceutical packaging and drug delivery innovations. Connect in Pharma is the cost-effective market tool that aims to reach the epicentre of the pharma and biopharma industry. An
The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conference for the Nordic region. It has been connecting life science and healthcare industry leaders with international
Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world
The latest research news from the Nordic region
Science articles
Researchers at Karolinska Institutet have developed a molecular method able to detect whether or not bacteria respond to antibiotics within minutes. The findings are presented in the journal Nature Microbiology
Professor Jens Juul Holst has made discoveries that have strongly influenced how people with obesity or type 2 diabetes are treated today. Throughout a long career, this internationally recognized researcher
Professor Åslaug Helland is the recipient of the King Olav Vs Cancer Research Award 2023. “This is a great honor, and I am very happy about this recognition of the
In January 2023, the European Association for the Study of Obesity (EASO) and the Novo Nordisk Foundation (NNF) announced that they were establishing a new prize for an agenda-setting researcher
The Royal Institute of Art and SciLifeLab have connected the creative minds of artists and scientists and the outcome of this fusion is explored in an exhibition at SciLifeLab campus.
Henrik Toft Sørensen, Professor of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, is receiving the 2023 prize, accompanied by 1.5 million DKK. He receives the Prize in recognition of
Nordic Life Science
The latest clinical trials
Evaxion Biotech to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma at the 2023 ASCO annual meeting. “We are excited to report that the
A vaccine against Lyme disease is now being tested in Sweden. “A new vaccine will probably be on the market within a couple of years,” says Johan Sanmartin Berglund, Professor
AnaMar has announced results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis (SSc) characterized by lung
AlzeCure Pharma has received positive data from the clinical study with the non-opioid drug candidate ACD440, which is developed against peripheral neuropathic pain. The phase II data show that ACD440
Spago Nanomedical has announced that the final step in the preparations for the clinical phase I/IIa trial in cancer patients, Tumorad-01, with its leading candidate drug 177Lu-SN201 has begun in
Valo Therapeutics has announced that the first patient has been treated in its trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus) in three tumor types. PeptiCRAd-1 combines two clinically proven cancer
The first patient has been dosed in a Phase I trial of TILT Biotherapeutics’ oncolytic adenovirus TILT-123. The multi-centre open-label, phase I, dose-escalation trial will evaluate igrelimogene litadenorepvec (TILT-123) in
Cantargia has announced a successful safety review of the ten non-squamous non-small cell lung cancer (NSCLC) patients treated with its lead asset nadunolimab (CAN04) and carboplatin/pemetrexed in the phase I/IIa
A second planned interim analysis has been conducted of the ongoing clinical phase 1b study with the company’s vaccine candidate ALZ-101 against Alzheimer’s disease. The analysis shows positive data with
Sign up to our newsletter